A Conversation with John Sunderland, Johannes Czernin, and Thomas Hope. Read more about A Conversation with John Sunderland, Johannes Czernin, and Thomas Hope.
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. Read more about NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection? Read more about Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?
NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Read more about NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Summary of the First ISMRM-SNMMI Workshop on PET/MRI: Applications and Limitations. Read more about Summary of the First ISMRM-SNMMI Workshop on PET/MRI: Applications and Limitations.
Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities-Phase III Studies. Read more about Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities-Phase III Studies.
111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. Read more about 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.
Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. Read more about Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.
Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Read more about Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.
Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. Read more about Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes.
